Target intelligence / Profile preview

Mu, kappa, and delta opioid receptor (MOR, KOR, DOR)

Target
MOR, KOR, DOR
Molecular classification
G protein-coupled receptor (GPCR), Receptor, Transmembrane signaling receptor protein
01

Overview

Mu, kappa, and delta opioid receptors are class A G protein-coupled receptors primarily expressed in the central and peripheral nervous system, as well as other tissues. They bind endogenous opioid peptides (endorphins, enkephalins, dynorphins) and exogenous opioids (morphine, fentanyl, etc.), mediating analgesic effects as well as side effects such as euphoria, addiction, and respiratory depression. Each receptor subtype has distinct tissue distribution, endogenous ligand preference, and physiological roles: - Mu opioid receptor (MOR): Most widely expressed, vital for analgesia, respiratory depression, euphoria, dependence, and gastrointestinal effects. - Kappa opioid receptor (KOR): Mediates analgesia, diuresis, and dysphoria, and may have lower abuse potential for agonists. - Delta opioid receptor (DOR): Contributes to analgesia and mood regulation, with potential roles in inflammatory pain and psychiatric disorders. Opioid receptors remain critical therapeutic targets for pain and addiction, but clinical use is complicated by serious adverse effects and misuse potential. Recent research seeks biased ligands to enhance therapeutic benefit while minimizing harm

Other names
Mu opioid receptor (MOR)mu-type opioid receptorμ opioid receptorKappa opioid receptor (KOR)kappa-type opioid receptorκ opioid receptorDelta opioid receptor (DOR)delta-type opioid receptorδ opioid receptorOpioid receptor familyopioid receptors
02

Mechanism of action

Agonists: Bind and activate the receptor, leading to Gi/o protein signaling, inhibition of adenylyl cyclase, decreased cAMP, opening of potassium channels, closing of calcium channels, inhibition of neurotransmitter release (presynaptic), reduced neuronal excitability, and promotion of analgesia and other opioid effects Antagonists: Block receptor activation, preventing endogenous or exogenous ligand effects Biased agonists: Preferentially activate G protein- or β-arrestin–mediated pathways, potentially reducing side effects such as respiratory depression or dependence

03

Biological functions

Signal transductionAnalgesia (pain modulation)Reward and addictive behavior regulationMood regulationGastrointestinal motility regulationRespiratory controlDiuresis
04

Disease associations

Pain (acute and chronic)Addiction / Substance use disordersNeurodegenerative diseaseMood disorders (depression, anxiety)InflammationCardiovascular disease
05

Safety considerations

Addiction/dependenceToleranceRespiratory depression (particularly with MOR agonists)ConstipationDysphoria or psychotomimetic effects (mainly KOR agonists)Potential for overdose and deathMood disturbance (depression, anxiety) after chronic use or withdrawal
06

Interacting drugs

Morphine

16 more in the full profile.

07

Biomarkers

No established patient-selection biomarkers for opioid receptor targeting in clinical practiceInvestigational: receptor gene polymorphisms (e.g., OPRM1 A118G variant for MOR)expression levels of MOR/KOR/DOR in certain tissues

Beyond the preview

Go deeper on Mu, kappa, and delta opioid receptor (MOR, KOR, DOR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mu, kappa, and delta opioid receptor (MOR, KOR, DOR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call